Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing

Launched by UNIVERSITY OF ALABAMA AT BIRMINGHAM · Apr 17, 2025

Keywords

ClinConnect Summary

This clinical trial, called "Pharmacogenomics in Stroke," is exploring how genetic testing can help doctors make better medication choices for patients who have experienced a stroke or a temporary stroke-like event known as a transient ischemic attack (TIA). The goal is to see if understanding a patient's genetics can lead to more personalized and timely treatment while they are in the hospital.

To participate in this study, you must be between 18 and 89 years old and have been admitted to the University of Alabama at Birmingham hospital with symptoms of a minor stroke or a high-risk TIA. Participants should be eligible for a specific type of medication called dual antiplatelet therapy, which is given within 66 hours of their last known well time. If you join the trial, you will undergo genetic testing to help guide your treatment, and the study is currently looking for volunteers. It's an opportunity to contribute to research that could improve care for future stroke patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18-89 years of age
• • admitted to University of Alabama at Birmingham (UAB) main hospital with symptoms or signs of minor ischemic stroke, or high risk TIA
• • eligible to receive dual antiplatelet load (presented to the hospital within 66 hours of last known well)
• Exclusion Criteria:
• • diagnosis of atrial fibrillation, valvular heart disease, index stroke due to known hypercoagulability (subset of other determined etiology) or large vessel disease (culprit vessel stenosis of ≥50%)
• • prescribed anticoagulation prior to stroke
• • treated with intravenous thrombolysis
• • treated with mechanical thrombectomy
• • missing NIH Stroke Scale score